Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 32 of 110 Updated Nov 17, 2026

PT-141

Bremelanotide · Vyleesi

FDA-APPROVED · MELANOCORTIN RECEPTOR AGONIST (FDA-APPROVED)

▓ 99 indexed citations across PubMed (84), ClinicalTrials.gov (4), EuropePMC (11).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

99 citations across 9 tiers

Tap any tier to jump to that section of the bibliography.

Background

Bremelanotide, sold under the brand name Vyleesi, is a medication used to treat low sexual desire in women. Specifically it is used for low sexual desire which occurs before menopause and is not due to medical problems, psychiatric problems, or problems within the relationship. It is given by an injection just under the skin of the thigh or abdomen.

→ Wikipedia

Mechanism of action

MC4R agonist in CNS; induces sexual desire independent of vascular mechanisms

Researched effects

Libido and arousal enhancement in HSDD (FDA-approved)

Reported efficacy (trial readout)

  • Sexual Desire Score 0.35 FSFI-desire change

    RECONNECT integrated bre (Phase 3, 24wk)

    High confidencePhase 3

Trial-efficacy data current as of November 16, 2026.

Live evidence

FDA label safety

Contraindications

4 CONTRAINDICATIONS VYLEESI is contraindicated in patients who have uncontrolled hypertension or known cardiovascular disease [see Warnings and Precautions ( 5.1 )]. Uncontrolled hypertension or known cardiovascular disease. ( 4 )

Full FDA label (DailyMed) →

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

1.75 mg SC 45 min before sex (FDA label)

→ FDA Vyleesi (bremelanotide) prescribing information, 1.75 mg SC PRN, max 1 dose per 24 h, max 8 doses per month

Known concerns

Nausea (~40%); flushing; headache; transient BP increase; focal hyperpigmentation

Top-ranked picks

10 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options.

    Journal of minimally invasive gynecology · 2026 — META-ANALYSES · AUTHORITY 94.5

  2. The effect of melanocortin-4 receptor agonist drugs on obesity and metabolic risk factors: a systematic review and meta-analysis.

    2025 — META-ANALYSES · AUTHORITY 94.5

  3. Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women.

    Journal of sex research · 2021 — META-ANALYSES · AUTHORITY 94.1

  4. Failure of a Meta-analysis: A Commentary on Glen Spielmans's "Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder in Women'".

    Journal of sex research · 2021 — META-ANALYSES · AUTHORITY 94.1

  5. Female Sexual Dysfunction and the Placebo Effect: A Meta-analysis.

    Obstetrics and gynecology · 2018 — META-ANALYSES · AUTHORITY 93.8

  6. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.

    The Annals of pharmacotherapy · 2020 — SYSTEMATIC REVIEWS · AUTHORITY 84.0

  7. 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

    2015 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 74.5

  8. 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

    2014 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 74.4

  9. Safety Profile of Bremelanotide Across the Clinical Development Program.

    Journal of women's health (2002) · 2022 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 74.2

  10. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.

    Journal of women's health (2002) · 2022 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 74.2

Full citation library

Year distribution

Meta-Analyses

5
  1. 1.

    Spielmans GI · Journal of sex research · 2021 · PMID 33678061

    Kingsberg et al. described results from two 24-week Phase III trials of bremelanotide for treating hypoactive sexual desire disorder (HSDD) in women. 72.72% of protocol-listed outcomes were not reported by Kingsberg et al., who provided results of 15 secondary measures which were not listed in the study protocols. None of their efficacy outcomes were reported in line with CONSORT data reporting standards and no secondary outcome had a stated rationale or cited evidence of validity. My meta-analy…

  2. 2.

    Toledo RG, Winkelman WD, Reyes-Gonzalez D, Bergeron S, et al. · Journal of minimally invasive gynecology · 2026 · PMID 40543759

    To conduct a systematic review and meta-analysis of treatments for female sexual desire, arousal, and orgasmic dysfunction in patients without sexual pain conditions. MEDLINE, Embase, Web of Science, Cochrane Library, PsycINFO, and ClinicalTrials.gov. Following the initial search in December 2024, a total of 8994 abstracts were screened, 278 full-text articles were reviewed, and 36 studies met criteria for data abstraction including a patient population with female sexual dysfunction (FSD) of de…

  3. 3.

    Weinberger JM, Houman J, Caron AT, Patel DN, et al. · Obstetrics and gynecology · 2018 · PMID 29995725

    To quantify the placebo effect of various pharmacologic modalities including neuromodulators, hormonal agents, and onabotulinum toxin A for female sexual dysfunction. Using Meta-analyses Of Observational Studies in Epidemiology guidelines, we conducted a systematic review of PubMed, EMBASE, ClinicalTrials.gov, and the Cochrane Review databases. Eleven search terms, "female sexual dysfunction" "treatment" in combination with "hypoactive sexual desire," "arousal disorder," "sexual pain disorder,"…

  4. 4.

    Kingsberg SA, Clayton AH, Portman D, Krop J, et al. · Journal of sex research · 2021 · PMID 33835907

  5. 5.

Systematic Reviews

1
  1. 6.

    Mayer D, Lynch SE · The Annals of pharmacotherapy · 2020 · PMID 31893927

Randomised Controlled Trials

14
  1. 7.

    Kingsberg SA, Clayton AH, Portman D, Williams LA, et al. · Obstetrics and gynecology · 2019 · PMID 31599840

    To evaluate the safety and efficacy of bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder. Two identical phase 3, randomized, double-blind, placebo-controlled, multicenter clinical trials (RECONNECT) evaluated the safety and efficacy of bremelanotide 1.75 mg administered subcutaneously as needed in premenopausal women with hypoactive sexual desire disorder. Patients were randomized 1:1 to 24 weeks of treatment with bremelanotide or placebo. Sample size…

  2. 8.

    Clayton AH, Kingsberg SA, Portman D, Sadiq A, et al. · Journal of women's health (2002) · 2022 · PMID 35147466

  3. 9.

    Diamond LE, Earle DC, Heiman JR, Rosen RC, et al. · The journal of sexual medicine · 2006 · PMID 16839319

    Melanocortins affect multiple physiological responses, including sexual behaviors. Bremelanotide is a synthetic peptide melanocortin analog of alpha-melanocyte-stimulating hormone that is an agonist at melanocortin receptors MC3R and MC4R. To evaluate a single intranasal dose of bremelanotide for potential effects on physiological and subjective measurements of sexual arousal and desire in premenopausal women with sexual arousal disorder. Change in vaginal pulse amplitude during neutral and erot…

  4. 10.

    Simon JA, Kingsberg SA, Portman D, Jordan R, et al. · Journal of women's health (2002) · 2022 · PMID 35230162

  5. 11.

    Althof S, Derogatis LR, Greenberg S, Clayton AH, et al. · The journal of sexual medicine · 2019 · PMID 31277966

    Responder analyses are used to determine whether changes that occur during a clinical trial are clinically meaningful; for subjective endpoints such as those based on patient-reported outcomes (PROs), responder analyses are particularly useful. To identify the minimal clinically important difference (MCID) for selected scores on questionnaires assessing female sexual functioning and to use these differences to analyze the response in a large, controlled, phase 2b, dose-finding study of bremelano…

  6. 12.

    Safarinejad MR, Hosseini SY · The Journal of urology · 2008 · PMID 18206919

    We evaluated the safety and efficacy of intranasal bremelanotide in men with erectile dysfunction who did not respond to sildenafil. A total of 342 married men (28 to 59 years old) with erectile dysfunction who did not respond to sildenafil were randomly assigned to receive 10 mg bremelanotide as an intranasal spray (group 1, 172) 45 minutes to 2 hours prior to sexual stimulation, or a similar regimen of placebo (group 2, 170). Patients were asked to use at least 16 doses/attempts at home. They…

  7. 13.

    Koochaki P, Revicki D, Wilson H, Pokrzywinski R, et al. · Journal of women's health (2002) · 2021 · PMID 33538638

  8. 14.

    Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, et al. · Women's health (London, England) · 2016 · PMID 27181790

    Evaluate efficacy/safety of bremelanotide (BMT), a melanocortin-receptor-4 agonist, to treat female sexual dysfunctions in premenopausal women. Patients randomized to receive placebo or BMT 0.75, 1.25 or 1.75 mg self-administered subcutaneously, as desired, over 12 weeks. Primary end point was change in satisfying sexual events/month. Secondary end points included total score changes on female sexual function index and female sexual distress scale-desire/arousal/orgasm. Efficacy data, n = 327. F…

  9. 15.

    White WB, Myers MG, Jordan R, Lucas J · Journal of hypertension · 2017 · PMID 27977473

    Melanocortin receptor agonists that bind to the melanocortin receptor 4 may cause increases in blood pressure (BP). Bremelanotide is an on-demand, subcutaneous melanocortin-receptor agonist that binds to the melanocortin receptor 4 and is being developed for the treatment of female sexual dysfunction. We studied the effects of bremelanotide administration on ambulatory BP and heart rate (HR), in a randomized, double-blind, placebo-controlled, and parallel-arm trial of three doses of bremelanotid…

  10. 16.

    Diamond LE, Earle DC, Garcia WD, Spana C · Urology · 2005 · PMID 15833522

    To evaluate the safety and pharmacodynamic effect of co-administration of subtherapeutic doses of PT-141, a cyclic heptapeptide melanocortin analogue, and sildenafil to patients with erectile dysfunction. Nineteen patients with erectile dysfunction who were responders to either Viagra or Levitra by self-report were given 25 mg sildenafil and 7.5 mg intranasal PT-141, 25 mg sildenafil and an intranasal placebo spray, and a placebo tablet and an intranasal placebo spray in a randomized cross-over…

  11. 17.

    Rosen RC, Diamond LE, Earle DC, Shadiack AM, et al. · International journal of impotence research · 2004 · PMID 14999221

    PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following subcutaneous administration to healthy male subjects and to patients with erectile dysfunction (ED) who report an inadequate response to Viagra. An inadequate response was defined for this study by patient report indicating that achievement of an erection suitable for vaginal penetration occurred < or =50% of the time while taking 100 mg Viagra. Erectile responses were assessed by RigiScan in healthy subjects in the absen…

  12. 18.

    Clayton AH, Lucas J, DeRogatis LR, Jordan R · Clinical therapeutics · 2017 · PMID 28189361

    This was a Phase I study to evaluate the safety, tolerability, and hemodynamic and pharmacokinetic effects of bremelanotide (BMT) coadministered with ethanol to healthy male and female participants. This was a randomized, placebo-controlled, double-blind, 3-period, 3-way crossover study. Individuals meeting the inclusion/exclusion criteria received BMT or placebo with or without ethanol at the research facility for 7 consecutive days. Participants were randomized to receive 1 of 6 treatment path…

  13. 19.

    Safarinejad MR · The journal of sexual medicine · 2008 · PMID 18179455

    This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the Editor-in-Chief. Following the retraction of Dr. Safarinejad's work by other journals, The Journal of Sexual Medicine has undertaken an extensive re-review of all papers Dr. Safarinejad published with the journal. Following an intensive re-evaluation and close scrutiny of the manuscripts,…

  14. 20.

    Diamond LE, Earle DC, Rosen RC, Willett MS, et al. · International journal of impotence research · 2004 · PMID 14963471

    PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following intranasal administration in healthy male subjects and in Viagra-responsive erectile dysfunction (ED) patients. Erectile response was assessed by RigiScan trade mark in healthy subjects without visual sexual stimulation (VSS) and in Viagra-responsive ED patients with VSS. In healthy subjects, mean C(max) and AUC((0-t)) increased in a dose-dependent manner. Median T(max) was 0.50 h and mean t(1/2) ranged from 1.85 to 2.09…

Clinical Trials

1
  1. 21.

    Molinoff PB, Shadiack AM, Earle D, Diamond LE, et al. · Annals of the New York Academy of Sciences · 2003 · PMID 12851303

    PT-141, a synthetic peptide analogue of alpha-MSH, is an agonist at melanocortin receptors including the MC3R and MC4R, which are expressed primarily in the central nervous system. Administration of PT-141 to rats and nonhuman primates results in penile erections. Systemic administration of PT-141 to rats activates neurons in the hypothalamus as shown by an increase in c-Fos immunoreactivity. Neurons in the same region of the central nervous system take up pseudorabies virus injected into the co…

Trial Registrations (ClinicalTrials.gov)

4
  1. 22.

    NCT02333071 · Phase 3 · Completed · 2014

    Conditions: Hypoactive Sexual Desire Disorder

  2. 23.

    NCT02338960 · Phase 3 · Completed · 2015

    Conditions: Hypoactive Sexual Desire Disorder

  3. 24.

    NCT01382719 · Phase 2 · Completed · 2011

    Conditions: Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder

  4. 25.

    NCT00425256 · Phase 2 · Completed · 2006

    Conditions: Sexual Arousal Disorder

Reviews

41
  1. 26.

    Nappi RE, Tiranini L, Martini E, Bosoni D, et al. · The Urologic clinics of North America · 2022 · PMID 35428435

    Female sexual dysfunction (FSD) comprises multiple overlapping sexual disorders with a multifaceted cause within the frame of the biopsychosocial model. Health care providers can screen for FSD according to their level of expertise and deliver at least basic counseling before eventually referring to sexual medicine specialists for specific care. The therapeutic algorithm comprises a multidisciplinary approach, including pharmacologic and nonpharmacologic management. Flibanserin and bremelanotide…

  2. 27.

    Dhillon S, Keam SJ · Drugs · 2019 · PMID 31429064

    Bremelanotide (Vyleesi™) is a melanocortin receptor agonist recently approved in the USA for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty. It is a self-administered, on-demand subcutaneous therapy. Initially developed by Palatin Technologies who sponsored the Phase 3 clinical trials, bremelanotide was subsequently out-licensed to AMAG Pharmace…

  3. 28.

    Hedlund P · Current opinion in investigational drugs (London, England : 2000) · 2004 · PMID 15134289

    Palatin, under license from Competitive Technology, is developing the peptide PT-141, a synthetically modified analog of PT-14, as a nasal spray for the potential treatment of erectile dysfunction (ED) and female sexual dysfunction. In September 2003, Palatin had completed a phase IIb trial in patients with ED and in February 2004, Palatin planned to start phase III trials in early 2005.

  4. 29.

    Pettigrew JA, Novick AM · Journal of midwifery & women's health · 2021 · PMID 34510696

    Nearly half of women in the United States report problems with sexual function. Many health care providers do not ask about sexual concerns during routine clinical encounters because of personal discomfort, lack of familiarity with treatment, or the belief that they lack adequate time to address this complex issue. This may be especially true for hypoactive sexual desire disorder (HSDD), the most commonly identified sexual problem among women. HSDD is characterized by a deficiency of sexual thou…

  5. 30.

    Cipriani S, Alfaroli C, Maseroli E, Vignozzi L · Expert opinion on pharmacotherapy · 2023 · PMID 36242769

    Female sexual response implies a deep intertwining between psychosocial and neurobiological mediators. Regulation of central melanocortin signaling may enhance sexual desire. In premenopausal women with hypoactive sexual desire disorder (HSDD), melanocortin receptor agonist bremelanotide (Vyleesi) has been hypothesized to trigger excitatory brain pathways. Hereby we summarize bremelanotide's proposed mechanism of action, pharmacokinetics, efficacy and safety data derived from clinical trials. A…

  6. 31.

    Sweeney P, Gimenez LE, Hernandez CC, Cone RD · Nature reviews. Endocrinology · 2023 · PMID 37365323

    A large body of preclinical and clinical data shows that the central melanocortin system is a promising therapeutic target for treating various metabolic disorders such as obesity and cachexia, as well as anorexia nervosa. Setmelanotide, which functions by engaging the central melanocortin circuitry, was approved by the FDA in 2020 for use in certain forms of syndromic obesity. Furthermore, the FDA approvals in 2019 of two peptide drugs targeting melanocortin receptors for the treatment of gener…

  7. 32.

    Mintzes B, Tiefer L, Cosgrove L · Drug and therapeutics bulletin · 2021 · PMID 34642243

    The US Food and Drug Administration (FDA) has approved two drugs for 'hypoactive sexual desire disorder' in women, flibanserin (Addyi) in 2015 and bremelanotide (Vyleesi) in 2019. In this paper we examine the outcome measures and clinical trial data upon which regulatory approval was based. In clinical trials, flibanserin led to an average of only one additional enjoyable sexual experience every two months, bremelanotide to none. Trials for both drugs feature shifts in primary outcomes and a con…

  8. 33.

    Edinoff AN, Sanders NM, Lewis KB, Apgar TL, et al. · Neurology international · 2022 · PMID 35076581

    Hypoactive sexual desire disorder (HSDD) is a persistent deficiency or absence of sexual fantasies and desire resulting in significant distress or interpersonal difficulty. Women with this disorder may display a lack of motivation for sexual activity, reduced responsiveness to erotic cues, a loss of interest during sexual activity, and avoidance of situations that could lead to sexual activity. The pathophysiology of HSDD is thought to be centered around inhibitory and excitatory hormones, neuro…

  9. 34.

    Spielmans GI, Ellefson EM · Journal of sex research · 2024 · PMID 36809187

    Efficacy outcomes are only informative to the extent that they are validated. We examined the measurement properties of efficacy measures from the phase III ("RECONNECT") bremelanotide trials for hypoactive sexual desire disorder (HSDD) in women. Continuous efficacy outcomes, including a) the Female Sexual Function Index (FSFI) and its Desire domain (FSFI-D) and b) the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) and its item assessing distress due to low desire (FSDS-DAO #13) h…

  10. 35.

    The Medical letter on drugs and therapeutics · 2019 · PMID 31381550

  11. 36.

    Pfaus JG, Sadiq A, Spana C, Clayton AH · CNS spectrums · 2022 · PMID 33455598

    Hypoactive sexual desire disorder (HSDD) is a common female sexual dysfunction and is estimated to affect approximately 10% of women in the United States. It has been suggested that HSDD is associated with an imbalance of hormone and neurotransmitter levels in the brain, resulting in decreased excitation, increased inhibition, or a combination of both. Evidence suggests neurotransmitters, including dopamine (DA), norepinephrine, and serotonin, as well as hormones such as estradiol and testostero…

  12. 37.

    How A, Jowdy C, Novatcheva E, Clayton AH · Clinical obstetrics and gynecology · 2025 · PMID 39846877

    This review evaluates pharmacologic treatments for female sexual dysfunction (FSD), focusing on hypoactive sexual desire disorder (HSDD). We provide clinically relevant applications for Food and Drug Administration (FDA)-approved medications (flibanserin and bremelanotide) and investigational therapies (Lorexys and testosterone combinations). Detailed study outcomes, safety profiles, and clinical strategies guide clinicians in appropriate diagnosis, patient selection, expectation setting, side e…

  13. 38.

    Lee JH, Lee JE, Harsh V, Clayton AH · Current psychiatry reports · 2022 · PMID 35102537

    This review article discusses the controversy in the DSM-5 conceptualization and diagnostic criteria for female sexual dysfunction (FSD). An overview of recent studies on available treatments for hypoactive sexual desire disorder (HSDD), female sexual arousal disorder (FSAD), and genitopelvic pain/penetration disorder (GPPD) is provided. Include delineation of the process of care for pre- and postmenopausal women with HSDD; release of global position statement on testosterone therapy in women; u…

  14. 39.

    Burton CS, Mishra K · Current opinion in obstetrics & gynecology · 2022 · PMID 36036468

    Sexual problems are reported by up to 45% of individuals assigned female at birth. Although sexual function is a complex biopsychosocial construct, there are a number of pharmacologic treatment options aimed at addressing the changing vaginal hormonal milieu in postmenopausal individuals and moderating the excitatory and inhibitory aspects of the central nervous system in those with hypoactive sexual desire disorder. The last decade has seen an increase in the number and type of pharmacologic tr…

  15. 40.

    Shadiack AM, Sharma SD, Earle DC, Spana C, et al. · Current topics in medicinal chemistry · 2007 · PMID 17584134

    Melanocortinergic agents are currently being investigated for a possible therapeutic role in male and female sexual dysfunction. These investigations were sparked by findings that systemic administration of a synthetic analog of alpha-MSH, MT-II, causes penile erections in a variety of species, including humans. Several other melanocortinergic agents including HP-228, THIQ, and bremelanotide (PT-141) have since been shown to have erectogenic properties thought to be due to binding to melanocorti…

  16. 41.

    Barakeh D, Mdaihly H, Karaoui LR · The Annals of pharmacotherapy · 2025 · PMID 38767282

    This review aims to provide an overview of pharmacologic management for hypoactive sexual desire disorder (HSDD) in premenopausal women, with a focus on available agents. Through a literature search on PubMed, Google Scholar, and ClinicalTrials.gov from 1999 to 2024, studies were selected using the following MeSH search terms: hypoactive sexual desire disorder, premenopause, pharmacologic management, flibanserin, bremelanotide, buspirone, bupropion, and testosterone, excluding those involving po…

  17. 42.

    Ila V, Pozzi E, Gamage M, Ramasamy R · Expert opinion on pharmacotherapy · 2025 · PMID 40069591

    Erectile dysfunction (ED) pathophysiology involves complex interactions between vasculogenic, hormonal, and neurological mechanisms, with endothelial dysfunction and oxidative stress playing crucial roles. There is growing interest in intravenous (IV) peptides and amino acids as potential therapeutic options for ED treatment. This narrative review examines recent developments in peptide and amino acid therapies for ED, focusing on PT-141, PnPP-19, L-arginine, and L-citrulline. The literature sea…

  18. 43.

    Yuan XC, Tao YX · Biomolecules · 2022 · PMID 36291616

    The discovery of melanocortins in 1916 has resulted in more than 100 years of research focused on these peptides. Extensive studies have elucidated well-established functions of melanocortins mediated by cell surface receptors, including MSHR (melanocyte-stimulating hormone receptor) and ACTHR (adrenocorticotropin receptor). Subsequently, three additional melanocortin receptors (MCRs) were identified. Among these five MCRs, MC3R and MC4R are expressed primarily in the central nervous system, and…

  19. 44.

    Fuhrman J, Yun J, Indorf A · Expert review of clinical pharmacology · 2025 · PMID 41088800

    Vasomotor symptoms (VMS) and decreased libido are common menopausal symptoms. Patients with breast cancer receiving endocrine therapy experience new or worsening menopausal symptoms. Pharmacologic therapy for VMS has been centered on selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors, gabapentin, and clonidine. These therapeutic options fall short in obtaining adequate symptom relief, illustrating a therapeutic gap in efficacious treatment modalities. There…

  20. 45.

    Hadley ME, Dorr RT · Peptides · 2006 · PMID 16412534

    The melanocortins (MCs) are a family of multifunctional peptidergic hormones. Several superpotent, prolonged acting, enzymatically resistant, MC analogs have been designed and synthesized to help clarify the nature and role of MCs and their receptors (MCRs) in physiological functions. Two of these analogs, a linear peptide, melanotan I, and a cyclic truncated peptide, melanotan II (MTI and MTII, respectively) have been patented and tested clinically for studies on tanning of the skin (MTI) and f…

  21. 46.

    Both S · Current sexual health reports · 2017 · PMID 29225554

    This review summarizes the recent literature and empirical studies on psychopharmacological approaches to treating female sexual interest/arousal disorder (FSIAD). Several new drugs for FSIAD that are intended to increase sexual responsiveness by influencing central excitatory and inhibitory neuromodulatory processes are under development. Studies on flibanserin resulted in the first approved medication for the treatment of low sexual desire in premenopausal women. New drugs under development ar…

  22. 47.

    Hellstrom WJ · International journal of impotence research · 2008 · PMID 18552830

    Currently available agents for erectile dysfunction (ED) share the same mechanism of action and pharmacologic properties. Therefore, they share the same limitations, including a principal focus on erection as an end-organ process. One of the relatively unexplored areas of research has been the potential for centrally acting agents to improve male sexual response. A variety of neurohormones and neurotransmitter systems are involved in the male sexual response, including testosterone, dopamine, se…

  23. 48.

    Shadiack AM, Althof S · International journal of impotence research · 2008 · PMID 18552829

    The neurobiology of sexual behavior involves the interrelationships between sex steroids and neurotransmitters that result in both central nervous system (CNS) effects and effects in the genitalia. Tools such as positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) scanning can help determine what areas of the brain are activated under sexual stimulation. Our understanding of the role of various neurotransmitters, neurosteroids and other CNS-acting compounds is impr…

  24. 49.

    da Silva Lara LA, Rufino AC, Oliveira FF, Rossato S, et al. · Minerva obstetrics and gynecology · 2022 · PMID 35147017

    There are different types of female sexual dysfunctions (FSDs), and FSD in general has a high prevalence worldwide. Studies of FSD should consider it as a multifactorial disorder that has biological, psychological, environmental, and relational aspects. In this review we discuss the available therapeutic interventions for FSD. For the current narrative review the PubMed database was searched to identify all publications up to 30 March 2021 that were systematic reviews and meta-analyses which exa…

  25. 50.

    Mavrych V, Shypilova I, Bolgova O · Frontiers in aging · 2026 · PMID 42021992

    Peptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline. To comprehensively review the mechanisms, clinical applications, evidence base, and safety profiles of therapeutic peptides with demonstrated or potential applications in healthy aging and age-related conditions. A comprehensive narrative review was conducted through systematic…

  26. 51.

    Kumar R, Nehra A · The Urologic clinics of North America · 2011 · PMID 21621083

    Several centrally acting agents have shown potential to improve erectile function in men with ED. They still lack adequate data in efficacy and tolerability. Nasal formulations of apomorphine and bremelanotide seem to be the most likely candidates for future approval. They may play a role, specifically in men who fail phosphodiesterase 5 (PDE5) therapy, are unable to take PDE5 inhibitors because of side effects, or are on nitrate therapy. This article reviews the centrally acting agents and the…

  27. 52.

    Pyke RE, Clayton AH · Sexual medicine reviews · 2018 · PMID 29576442

    Regarding hypoactive sexual desire disorder (HSDD) in women, some reviewers judge the effect size small for medications vs placebo, but substantial for cognitive behavior therapy (CBT) or mindfulness meditation training (MMT) vs wait list. However, we lack comparisons of the effect sizes for the active intervention itself, for the control treatment, and for the differential between the two. For efficacy trials of HSDD in women, compare effect sizes for medications (testosterone/testosterone tran…

  28. 53.

    Cocchetti C, Ristori J, Mazzoli F, Vignozzi L, et al. · International journal of impotence research · 2020 · PMID 33558671

    Hypoactive sexual desire disorder (HSDD) represents a common condition among transgender women. However, to date no specific guidelines for the management of HSDD in transgender persons are available. The aim of the present narrative Review is to evaluate evidence-based treatment for HSDD and to suggest treatment options for HSDD in transgender women. Clinically relevant publications on the management of HSDD (from 1985 to 2020) were searched in PubMed and Medline databases, using the following…

  29. 54.

    Guptan N, Simon JA · Journal of sex & marital therapy · 2026 · PMID 42144994

    Women with hypoactive sexual desire disorder (HSDD) lack the thoughts, desire, or receptivity to sexual desire, causing personal difficulty and distress (DSM IV-TR). However, HSDD clinical trials evaluating testosterone therapy, flibanserin, and bremelanotide spanning nearly a decade show women with HSDD, encompassing low to no sexual desire, are still engaging in sexual activity. We aimed to define this sexual activity as "mercy sex", quantify its frequency, and provide hypothetical explanation…

  30. 55.

    Clayton AH, Kingsberg SA, Goldstein I · Sexual medicine · 2018 · PMID 29523488

    Hypoactive sexual desire disorder (HSDD) often has a negative impact on the health and quality of life of women; however, many women do not mention-let alone discuss-this issue with their physicians. Providers of gynecologic services have the opportunity to address this subject with their patients. To review the diagnosis and evidence-based treatment of low sexual desire in women with a focus on strategies that can be used efficiently and effectively in the clinic. The Medline database was searc…

  31. 56.

    Ronghe V, Pannase K, Gomase KP, Mahakalkar MG · Cureus · 2023 · PMID 38161863

    Hypoactive Sexual Desire Disorder (HSDD) is a complex and multifaceted condition that significantly impacts the sexual well-being and overall quality of life of women. This comprehensive review aims to provide a holistic understanding of HSDD by exploring its etiology, diagnostic criteria, treatment approaches, and broader societal implications. The review delves into the intricate interplay of biological factors, including hormonal changes and neurotransmitter imbalances, that contribute to HSD…

  32. 57.

    Miller MK, Smith JR, Norman JJ, Clayton AH · Expert opinion on emerging drugs · 2018 · PMID 30251897

    Female sexual dysfunction (FSD) is a highly prevalent, yet commonly underdiagnosed and undertreated condition. This paper reviews the diagnostic terminology for FSD, and basic sexual physiology in women. The Food and Drug Administration (FDA) approved drugs for FSD are discussed, followed by investigational drugs for FSD currently in phase 2 or 3 clinical trials, reasons for failure of drug development, and potential future drug targets. Areas covered: A literature review was conducted for avail…

  33. 58.

    Belkin ZR, Krapf JM, Goldstein AT · Expert opinion on investigational drugs · 2015 · PMID 25376023

    There is growing recognition of female sexual dysfunction (FSD) as an important women's health concern. Despite an increased awareness of the pathophysiologic components to FSD, currently, there are no drugs approved for the most common sexual complaint in women-decreased sexual desire. In response to an overwhelming demand for therapy for FSD, several drugs are undergoing development and testing. The aim of this paper is to provide the latest data on pharmacological treatments for FSD currently…

  34. 59.

    Carson CC · Current urology reports · 2007 · PMID 18042327

    Recent animal studies have resulted in newer central nervous system (CNS)-acting agents for the treatment of sexual dysfunction in men and women. CNS stimulation and control of sexual function primarily originates in the hypothalamus, medial preoptic area, and paraventricular nucleus. Neurotransmitters responsible for sexual function, such as serotonin, dopamine, and oxytocin, can be manipulated pharmacologically. Early clinical trials and use of apomorphine have shown limited success and accept…

  35. 60.

    Croft HA · The journal of sexual medicine · 2017 · PMID 29198512

    The neurobiology of sexual response is driven in part by dopamine and serotonin-the former modulating excitatory pathways and the latter regulating inhibitory pathways. Neurobiological underpinnings of hypoactive sexual desire disorder (HSDD) are seemingly related to overactive serotonin activity that results in underactive dopamine activity. As such, pharmacologic agents that decrease serotonin, increase dopamine, or some combination thereof, have therapeutic potential for HSDD. To review the r…

  36. 61.

    de Oliveira L, Vignozzi L, Giraldi A, Varod S, et al. · Pharmacology · 2024 · PMID 38151009

    Hypoactive sexual desire disorder (HSDD) in premenopausal women involves biological, psychological, and social aspects. In the European Society for Sexual Medicine meeting in Rotterdam in February 2023, several leading experts in the field discussed the multifaceted nature of this disorder and the state of the art regarding treatment at a round table. This review reflects the information discussed at this event and further discusses current controversies. HSDD is the most prevalent female-estima…

  37. 62.

    Perelman MA · The journal of sexual medicine · 2007 · PMID 17958620

    Human sexual response involves a complex sequencing of interrelated mind/body processes. Few treatment options exist that address the complex multilayered etiological determinants of female sexual dysfunction (FSD). Review and evaluate the clinical application of centrally acting agents for the treatment of FSD, with particular emphasis on recently released data on bremelanotide. Review of literature on the treatment of FSD. Approaches to FSD treatment have ranged from psychological counseling t…

  38. 63.

    Ückert S, Bannowsky A, Albrecht K, Kuczyk MA · Expert opinion on investigational drugs · 2014 · PMID 25096243

    Over the last 20 years, basic and clinical research activities studying the male and female sexual responses have led to several pharmacological options to treat male erectile dysfunction (ED) and female arousal and orgasmic disorders. While some strategies exclusively focus on peripheral mechanisms--such as nitric oxide/cyclic GMP signaling, which is known to play a role in the control of genital vascular and nonvascular smooth muscle--others have considered the central pathways involved in med…

  39. 64.

    Tran L, Nguyen TD, Gad AG, Shaaban E, et al. · Drug development research · 2026 · PMID 42041173

    d-Amino acids, the non-natural enantiomers of l-amino acids, have emerged as powerful tools in peptide drug development due to their unique biochemical properties. Their resistance to proteolytic degradation, enhanced conformational rigidity, and reduced immunogenicity make them especially valuable in designing long-acting and receptor-selective therapeutics. Since the mid-20th century, more than 20 FDA-approved drugs have incorporated at least one d-amino acid into their structure, spanning ind…

  40. 65.

    Kingsberg SA, Clayton AH, Pfaus JG · CNS drugs · 2015 · PMID 26519340

    How a woman responds to sexual cues is highly dependent on a number of distinct, yet related, factors. Researchers have attempted to explain the female sexual response for decades, but no single model reigns supreme. Proper female sexual function relies on the interplay of somatic, psychosocial and neurobiological factors; misregulation of any of these components could result in sexual dysfunction. The most common sexual dysfunction disorder is hypoactive sexual desire disorder (HSDD). HSDD is a…

  41. 66.

    Vasylieva V, West A, Karpman E · Sexual medicine reviews · 2026 · PMID 42862021

    Peptide-based therapies are increasingly used in urology and sexual medicine, although adoption is often influenced by off-label prescribing, direct-to-consumer promotion, and limited long-term safety data. We review mechanisms, clinical evidence, dosing, safety, and regulatory status of these agents. A structured search of PubMed, Scopus, and Google Scholar identified studies of peptide-based therapies in sexual medicine. Search terms included Bremelanotide, Melanotan II, Kisspeptin, Oxytocin,…

Research Articles

30
  1. 67.

    Zhang H, Chen LN, Yang D, Mao C, et al. · Cell research · 2021 · PMID 34433901

    Melanocortin-4 receptor (MC4R) plays a central role in the regulation of energy homeostasis. Its high sequence similarity to other MC receptor family members, low agonist selectivity and the lack of structural information concerning MC4R-specific activation have hampered the development of MC4R-seletive therapeutics to treat obesity. Here, we report four high-resolution structures of full-length MC4R in complex with the heterotrimeric G

  2. 68.

    Expert review of endocrinology & metabolism · 2006 · PMID 30290453

  3. 69.

    Suzuki S, Kitanaka C, Okada M · Anticancer research · 2024 · PMID 39197897

    Glioblastoma is the most aggressive form of brain tumor and has a dismal prognosis; therefore, novel therapeutic approaches based on the mechanisms underlying its aggressive nature are urgently required. A growing body of evidence suggests that neurotransmitters play a key role in modulating the biology of glioblastoma; however, the role of melanocortins remains unclear. The effects of bremelanotide, a melanocortin receptor agonist, alone or in combination with chemotherapeutic agents, on surviv…

  4. 70.

    Spana C, Jordan R, Fischkoff S · Diabetes, obesity & metabolism · 2022 · PMID 35170192

    The melanocortin 4 receptor (MC4R) plays a central role in appetite regulation, and agonistic activity at this receptor promotes satiety. Results from two randomized controlled clinical trials examine the effects of bremelanotide's agonism at MC4R on caloric intake and body weight. Premenopausal women with a body mass index >30 kg/m In Study A, 27 of 30 bremelanotide subjects (90.0%) completed the trial and exhibited a significantly greater reduction in body weight after 16 days versus placebo […

  5. 71.

    Pfaus J, Giuliano F, Gelez H · The journal of sexual medicine · 2007 · PMID 17958619

    Bremelanotide is an analogue of the naturally occurring peptide alpha-melanocyte-stimulating hormone (alpha-MSH). It stimulates erection in men and male rats, and is currently in clinical trials for the treatment of erectile dysfunction. To review the effects of bremelanotide, an analogue of the naturally occurring peptide alpha-MSH, on the preclinical indices of sexual desire in female rats, and where in the brain these actions may occur. Appetitive sexual behaviors, such as solicitations, hops…

  6. 72.

    Kim NN · Sexual medicine reviews · 2022 · PMID 35772848

  7. 73.

    Borland JM, Kohut-Jackson AL, Peyla AC, Hall MA, et al. · Neuropharmacology · 2025 · PMID 39793696

    Hypoactive sexual desire disorder (HSDD) is the most reported sexual dysfunction among premenopausal women worldwide. Bremelanotide, trade name Vyleesi, has been approved by the United States Food and Drug Administration to treat HSDD. However, despite approval, very little is known about its neurobiological mechanism of action. In this study, we utilized a female Syrian hamster model to investigate the effects of bremelanotide on melanocortin receptor expression in the mesolimbic dopamine syste…

  8. 74.

    Simon JA, Kingsberg SA, Portman D, Williams LA, et al. · Obstetrics and gynecology · 2019 · PMID 31599847

    To evaluate the long-term safety and efficacy of bremelanotide as treatment for hypoactive sexual desire disorder in premenopausal women. Women who completed the 24-week double-blind core phase of RECONNECT, composed of two parallel phase 3 trials (301 and 302) examining the safety and efficacy of bremelanotide compared with placebo in premenopausal women with hypoactive sexual desire disorder, could enroll in the 52-week open-label extension, provided they had not experienced serious adverse ev…

  9. 75.

    Sauter M, Uhl P, Burhenne J, Haefeli WE · Journal of pharmaceutical and biomedical analysis · 2020 · PMID 32353679

    Bremelanotide (Vyleesi®), a cyclic heptapeptide, was recently approved for the subcutaneous treatment of premenopausal hypoactive sexual desire disorder. To foster the development of alternative routes of administration, we aimed at determining the oral plasma pharmacokinetics of bremelanotide in beagle dogs. Therefore, we established a UHPLC-MS/MS assay with an LLOQ of 10 pg/mL (9.8 pM) using 100 μL of plasma and validated it according to the guidelines of the US Food and Drug Administration an…

  10. 76.

    Safarinejad MR, Hosseini SY · The Journal of urology · 2023 · PMID 36626345

  11. 77.

    Kingsberg SA, Simon JA · Journal of women's health (2002) · 2020 · PMID 32460605

    Hypoactive sexual desire disorder (HSDD) in women is defined as the persistent or recurrent absence of sexual thoughts or fantasies and/or lack of desire for sexual activity that is associated with marked personal distress and/or interpersonal difficulties, and cannot be better attributed to another primary disorder, medication, or general medical condition. Notably, HSDD shares some similarity with depression, as its etiology can be explained using a biopsychosocial model that includes biologic…

  12. 78.

    Porst H · Der Urologe. Ausg. A · 2003 · PMID 14569381

    Erectile dysfunction (ED) management in the following 3-5 years will be dominated by substances targeting the L-arginine-NO-guanylate cyclase-cGMP-PDE-5 pathway, resulting in an intracellular elevation of the cGMP concentrations. Promising alternatives to the PDE-5 inhibitors, such as guanylate cyclase activators and Rho-kinase inhibitors, may also effectively compliment a PDE-5 inhibitor. Intranasal application of the melanocortin agonist PT 141 (Melanotan II) seems to be promising. As schedule…

  13. 79.

    Mestria S, Odoardi S, Frison G, Strano Rossi S · Drug testing and analysis · 2021 · PMID 33245851

    The spread of performance and image enhancing drugs (PIEDs) often requires forensic toxicology laboratories to identify unknown compounds without reference standards. We characterized the PIEDs melanotan II and bremelanotide, not legally marketed, in eight unknown samples confiscated by police together with anabolic steroids, hormone modulators, sexual enhancers and stimulants, intended for the black market of bodybuilders, using liquid chromatography-high resolution/high accuracy Orbitrap mass…

  14. 80.
  15. 81.

    Nappi RE, Tiranini L, Cucinella L, Martini E, et al. · Expert opinion on pharmacotherapy · 2023 · PMID 35430926

    Female sexual dysfunctions (FSDs) are common in women of any age and have a huge impact on quality of life and relationships. They have a multifaceted etiology limiting the development of pharmacotherapies with a high rate of effectiveness. Safety issues are also a concern. The authors report the most recent advances in pharmacotherapy for premenopausal and postmenopausal women with a main focus on hypoactive sexual desire disorders (HSDD) and associated sexual symptoms. Good levels of evidence…

  16. 82.

    King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, et al. · Current topics in medicinal chemistry · 2007 · PMID 17584130

    Penile erection is a complex physiologic event resulting from the interactions of the nervous system on a highly specialized vascular organ. Activation of central nervous system melanocortinergic (MC) receptors with either endogenous or synthetic melanotropic ligands may initiate and/or facilitate spontaneous penile erection. While the CNS contains principally the MC3 and MC4 receptor subtypes, there is conflicting data as to which receptor mediates erection. Although the MC4R is emerging as the…

  17. 83.

    Pfaus JG, Shadiack A, Van Soest T, Tse M, et al. · Proceedings of the National Academy of Sciences of the United States of America · 2004 · PMID 15226502

    Disorders of sexual desire affect an estimated 30% of women in North America and Europe, with etiologies based on interpersonal, personal, and physiological factors. There are currently no pharmacological agents approved for use in the treatment of female sexual dysfunction. This is due, in part, to a focus on the effects of experimental drugs on reflexive components of sexual behavior, such as lordosis, in animal models. Here we report that PT-141, a peptide analogue of alpha-melanocyte-stimula…

  18. 84.

    Pfaus JG, Balon R · Journal of clinical psychopharmacology · 2026 · PMID 41960633

  19. 85.

    Nappi RE, Gardella B · Expert opinion on pharmacotherapy · 2019 · PMID 30806100

  20. 86.

    Mihulka O, Curran M, Narasimhan RM, Moore JF, et al. · Journal of minimally invasive gynecology · 2025 · PMID 41419078

    Sexual dysfunction is a common but underrecognized sequelae of breast and gynecologic cancer treatment. Many patients experience symptoms of genitourinary syndrome of menopause, including vaginal dryness, dyspareunia, and diminished sexual desire. Addressing these challenges requires a comprehensive, evidence-based approach to management. A comprehensive literature search was conducted using PubMed, Google Scholar, and Scopus to identify peer-reviewed studies published within the last 30 years.…

  21. 87.

    Aughton KL, Hamilton-Smith K, Gupta J, Morton JS, et al. · British journal of pharmacology · 2008 · PMID 18587425

    Hypothalamic neuropeptides centrally modulate sexual arousal. However, the role of neuropeptides in peripheral arousal has been ignored. Vascular and non-vascular smooth muscle relaxation in the vagina is important for female sexual arousal. To date, in vitro studies have focused on vaginal strips with no studies on vaginal arteries. The aim of this study was to compare the effects of sexual hypothalamic neuropeptides on rabbit vaginal wall strips and arteries. Tissue bath and wire myography tec…

  22. 88.

    2006 · PMID 31369224

    No information is available on the clinical use of bremelanotide during breastfeeding. Because bremelanotide is a cyclic peptide molecule with a molecular weight of 1025, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, bremelanotide should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

  23. 89.

    Prindle CR, Bennett TL, Rajewski BH, Kelley KJ, Impastato AC, Potterfield R, Marks DL, Delev JY. · 2026 · PMID 41907544

    The melanocortin system is a genetically conserved and clinically validated target for the treatment of obesity. Hundreds of studies establish the role of the melanocortin receptors, particularly the melanocortin-4 receptor, in food intake, weight control, and energy expenditure. Over the last several decades, the pharmaceutical industry pursued melanocortin-4 receptor-selective agonists for the treatment of general obesity. Many candidates failed to demonstrate meaningful weight loss in the cli…

  24. 90.

    Santos I, Cunha F, Andrade R, Castro N, Cabral R, Cunha C, Pires P, Melo B. · 2025

  25. 91.

    Al Musaimi O. · 2024 · PMID 38540684

    Peptides continue to gain significance in the pharmaceutical arena. Since the unveiling of insulin in 1921, the Food and Drug Administration (FDA) has authorised around 100 peptides for various applications. Peptides, although initially derived from endogenous sources, have evolved beyond their natural origins, exhibiting favourable therapeutic effectiveness. Medicinal chemistry has played a pivotal role in synthesising valuable natural peptide analogues, providing synthetic alternatives with th…

  26. 92.

    Ågmo A. · 2025 · PMID 40426419

    There has been an extensive search for efficient pharmacological treatment of female sexual interest/arousal disorder and other sexual dysfunctions. However, available treatments have met limited success, except for the drugs used for treating erectile deficiency. A possible reason for this may be that both the preclinical and clinical evaluation of treatment effects have been inadequate. The present literature review shows that the intensity of sexual approach behaviors in non-human animals app…

  27. 93.

    Weirath NA, Haskell-Luevano C. · 2024 · PMID 39296259

    The melanocortin receptors are a centrally and peripherally expressed family of Class A GPCRs with physiological roles, including pigmentation, steroidogenesis, energy homeostasis, and others yet to be fully characterized. There are five melanocortin receptor subtypes that, apart from the melanocortin-2 receptor (MC2R), are stimulated by a shared set of endogenous agonists. Until 2020, X-ray crystallographic and cryo-electron microscopic (cryo-EM) structures of these receptors were unavailable,…

  28. 94.

    Kim S, Cho MC, Cho SY, Chung H, Rajasekaran MR. · 2021 · PMID 32202086

    Currently, several treatments exist for the improvement of erectile dysfunction (ED). These include medical therapies such as phosphodiesterase type 5 inhibitors (PDE5-Is), invasive methods such as intracavernosal injection therapy of vaso-active substances, vacuum erection devices, and penile prosthesis implants. However, the percentage of patients that are unresponsive to available treatments and who drop out from treatments remains high. Current evidence reveals that the pathogenesis of ED is…

  29. 95.

    Pachano Pesantez GS, Clayton AH. · 2021 · PMID 34483765

    Hypoactive sexual desire disorder (HSDD) is a persistent or recurrent absence of sexual fantasies and desire for sexual activity, causing marked personal distress or interpersonal difficulties. HSDD affects 10% of U.S. women and is associated with depression and other negative emotional states. It is imperative that psychiatrists are competent to make this diagnosis and are aware of available treatment options. A full psychiatric and medical history are necessary to identify potential causes or…

  30. 96.

    Yuvaraaj VK, Sharma N · Analytical methods : advancing methods and applications · 2026 · PMID 42485063

    Bremelanotide (BRM) is a cyclic peptide therapeutic whose intrinsic stability and degradation behavior have not been extensively investigated. This study aimed to develop a stability-indicating RP-HPLC method for BRM and characterize its degradation products using LC-HRMS/MS combined with computational approaches. Stress degradation studies were conducted according to International Council for Harmonization guidelines under acidic, basic, neutral hydrolytic, oxidative, thermal, and photolytic co…

Preprints (not yet peer-reviewed)

2
  1. 97.

    Mendias CL, Awan TM. · 2026

    Peptides are a rapidly expanding drug class with a parallel and largely unregulated gray market that sells preparations directly to consumers for self-administration. The use of gray market peptides has grown substantially, with patients self-administering these compounds for purported benefits including accelerated musculoskeletal injury recovery, muscle hypertrophy, fat loss, and athletic performance enhancement. The objective of this study was to evaluate the purity, measured abundance, and e…

  2. 98.

    Zhang H, Chen L, Yang D, Mao C, Shen Q, Feng W, Shen D, Dai A, Xie S, Zhou Y, Qin J, Sun J, Scharf DH, Hou T, Zhou T, Wang M, Zhang Y. · 2021

    <h4>SUMMARY</h4> Melanocortin-4 receptor (MC4R) plays a central role in the regulation of energy homeostasis. Its high sequence similarity to other MC receptor family members, low agonist selectivity and the lack of structural information concerning receptor activation have hampered the development of MC4R-seletive therapeutics to treat obesity. Here, we report four high-resolution structures of full-length MC4R in complex with the heterotrimeric Gs protein stimulated by the endogenous peptide α…

Case Reports

1
  1. 99.

    Nelson ME, Bryant SM, Aks SE · Clinical toxicology (Philadelphia, Pa.) · 2012 · PMID 23121206

    Melanotan products are currently purchased over the Internet and are designed to induce melanogenesis to create sunless tanning as well are used as sexual stimulants. We report a novel case of systemic toxicity with sympathomimetic excess and rhabdomyolysis after use of Melanotan II. A 39 year-old Caucasian male injected subcutaneously 6 mg of Melanotan II purchased over the Internet in an attempt to darken his skin during wintertime. This dose was six times the recommended starting dose per the…

Curated sources on file

6
  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.

Continue reading